Champions Oncology

CSBR

시가총액 US$6542만

Champions Oncology's first-quarter fiscal 2027 results record revenue and margin growth, stronger adjusted earnings and surging data-license revenues.

Champions Oncology, Inc. (CSBR) Q1 2027 Earnings Call Transcript

Champions Oncology NASDAQ: CSBR reported first-quarter fiscal 2027 revenue growth, improved margins and its fifth consecutive quarter of positive adjusted EBITDA, as both its translational oncology services and data licensing businesses contributed to results.

Oncology services margin improves to 51%; Adjusted EBITDA increases to $671,000 HACKENSACK, NJ / ACCESS Newswire / September 10, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2027, ended July 31, 2026. First Quarter and Recent Highlights: Revenue of $15.2 million, an increase of 8.8% year over year Oncology services margin of 51%, compared with 43% in the prior-year period Adjusted EBITDA of $671,000, compared with $59,000 in the prior-year period Continued investment in the Company's commercial organization, data platform and strategic growth initiatives Robert Brainin, CEO of Champions, commented, "We delivered strong performance in the first quarter of fiscal 2027, with improved study execution and conversion in our core research services business driving higher revenue and materially better margins.

HACKENSACK, NJ / ACCESS Newswire / September 4, 2026 / Champions Oncology, Inc. (CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and operational results for the quarter ended July 31, 2026, on Thursday, September 10, 2026, after market close.

Champions Oncology reports fourth-quarter fiscal 2026 growth as revenue gains, margin improvement and operational initiatives support progress.

Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call Transcript

Champions Oncology NASDAQ: CSBR reported record revenue for fiscal 2026 and positive adjusted EBITDA in every quarter of the year, supported by growth in its core Translational Oncology Solutions, or TOS, services business and efforts to bring radiopharmaceutical work in-house.

Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA HACKENSACK, NJ / ACCESS Newswire / July 27, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2026. Fourth Quarter and Other Financial Highlights: Record annual revenue of $59.4 million Fourth quarter revenue of $13.8 million Fourth quarter oncology services margin of 51% Adjusted EBITDA of $158,000 for the quarter and $1.6 million for the fiscal year Adjusted EBITDA income all four quarters in FY 2026 Continued investment in radiopharmaceuticals, the data platform and commercial organization Robert Brainin, CEO of Champions, commented, "Fiscal 2026 marked a year of meaningful progress in executing our strategic priorities as we delivered record annual revenue while continuing to invest in the capabilities we believe will support our next phase of growth.

Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.